美农生物
(301156)
| 流通市值：13.50亿 | | | 总市值：21.01亿 |
| 流通股本：1.18亿 | | | 总股本：1.84亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 327,552,727.24 | 159,023,381.03 | 561,265,718.82 | 390,128,929.24 |
| 营业收入 | 327,552,727.24 | 159,023,381.03 | 561,265,718.82 | 390,128,929.24 |
| 二、营业总成本 | 299,318,883.41 | 138,733,565.05 | 504,072,553.74 | 348,508,534.53 |
| 营业成本 | 230,837,907.14 | 108,963,866.12 | 389,275,741.83 | 270,491,707.07 |
| 利息支出 | - | 0 | 0 | 0 |
| 手续费及佣金支出 | - | 0 | 0 | 0 |
| 退保金 | - | 0 | 0 | 0 |
| 赔付支出净额 | - | 0 | 0 | 0 |
| 提取保险合同准备金净额 | - | 0 | 0 | 0 |
| 保单红利支出 | - | 0 | 0 | 0 |
| 分保费用 | - | 0 | 0 | 0 |
| 税金及附加 | 2,405,210.65 | 1,254,827.71 | 4,096,371.7 | 2,867,103.17 |
| 销售费用 | 27,341,094.68 | 11,396,089.66 | 46,578,390.25 | 30,637,973.24 |
| 管理费用 | 21,945,827.76 | 10,183,876.28 | 39,482,975.73 | 29,280,094.08 |
| 研发费用 | 13,014,129.87 | 5,302,166.52 | 24,839,817.14 | 16,235,575.69 |
| 财务费用 | 3,774,713.31 | 1,632,738.76 | -200,742.91 | -1,003,918.72 |
| 其中:利息费用 | 3,381.56 | 1,681.64 | 6,952.7 | 5,289.16 |
| 其中:利息收入 | 510,843.54 | 271,981.98 | 1,731,904.17 | 1,448,410.94 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -588,166.42 | -63,258.8 | -224,366.52 | -586,922.96 |
| 加:投资收益 | 762,969.21 | 695,211.86 | 2,547,873.06 | 2,607,327.78 |
| 净敞口套期收益 | - | 0 | 0 | 0 |
| 汇兑收益 | - | 0 | 0 | 0 |
| 资产处置收益 | -97,956.57 | 0 | -3,262.16 | 2,189.66 |
| 资产减值损失(新) | -9,081,043.75 | -7,040,133.88 | -2,869,343.94 | -1,204,064.02 |
| 信用减值损失(新) | -1,141,519.59 | -306,052.86 | -1,032,593.87 | 177,217.3 |
| 其他收益 | 1,467,113.04 | 790,363.24 | 4,970,837.18 | 2,841,271.04 |
| 四、营业利润 | 19,555,239.75 | 14,365,945.54 | 60,582,308.83 | 45,457,413.51 |
| 加:营业外收入 | 68,237.95 | 0.87 | 444,858.23 | 427,915.56 |
| 减:营业外支出 | 121,974.38 | 3,418.8 | 257,704.96 | 112,011.58 |
| 五、利润总额 | 19,501,503.32 | 14,362,527.61 | 60,769,462.1 | 45,773,317.49 |
| 减:所得税费用 | 1,440,494.34 | 910,264.4 | 5,958,926.3 | 4,855,127.98 |
| 六、净利润 | 18,061,008.98 | 13,452,263.21 | 54,810,535.8 | 40,918,189.51 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 18,061,008.98 | 13,452,263.21 | 54,810,535.8 | 40,918,189.51 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 18,061,008.98 | 13,452,263.21 | 54,810,535.8 | 40,918,189.51 |
| 扣除非经常损益后的净利润 | 17,764,878.8 | 13,091,469.22 | 51,350,779.77 | 38,474,305.49 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0.1 | 0.39 | 0.29 |
| (二)稀释每股收益 | 0.1 | 0.1 | 0.39 | 0.29 |
| 九、综合收益总额 | 18,061,008.98 | 13,452,263.21 | 54,810,535.8 | 40,918,189.51 |
| 归属于母公司股东的综合收益总额 | 18,061,008.98 | 13,452,263.21 | 54,810,535.8 | 40,918,189.51 |
| 公告日期 | 2026-08-27 | 2026-04-28 | 2026-04-28 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |